Medicus Pharma gets FDA feedback and IRB nod for smaller Phase 2 trial

July 16, 2026 7:30 AM

Medicus Pharma Ltd. (NASDAQ: MDCX) said it received written feedback from the U.S. Food and Drug Administration and central Institutional ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found